These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7250178)

  • 21. Propafenone disposition in renal insufficiency and renal failure.
    Burgess E; Duff H; Wilkes P
    J Clin Pharmacol; 1989 Feb; 29(2):112-3. PubMed ID: 2715367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.
    Garcia MJ; Dominguez-Gil A; Tabernero JM; Sanchez Tomero JA
    Eur J Clin Pharmacol; 1979 Sep; 16(2):119-24. PubMed ID: 499308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed-Effects Analysis.
    Jaber MM; Takahashi T; Kirstein MN; Al-Kofahi M; Jacobson PA; Brundage RC
    J Clin Pharmacol; 2023 Jan; 63(1):135-142. PubMed ID: 36063026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
    Haubitz M; Bohnenstengel F; Brunkhorst R; Schwab M; Hofmann U; Busse D
    Kidney Int; 2002 Apr; 61(4):1495-501. PubMed ID: 11918757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.
    Maia J; Almeida L; Falcão A; Soares E; Mota F; Potgieter MA; Potgieter JH; Soares-da-Silva P
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):119-30. PubMed ID: 18397682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of hydrochlorothiazide in relation to renal function.
    Niemeyer C; Hasenfuss G; Wais U; Knauf H; Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(5):661-5. PubMed ID: 6873147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of naproxen in subjects with normal and impaired renal function.
    Anttila M; Haataja M; Kasanen A
    Eur J Clin Pharmacol; 1980 Oct; 18(3):263-8. PubMed ID: 7439246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
    Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.
    Wong SL; Menacherry S; Mulford D; Schmitz PJ; Locke C; Granneman GR
    Eur J Clin Pharmacol; 1997; 52(3):223-7. PubMed ID: 9218930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis.
    Wiegers U; Hanrath P; Kuck KH; Pottage A; Graffner C; Augustin J; Runge M
    Eur J Clin Pharmacol; 1983; 24(4):503-7. PubMed ID: 6407848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal disease and drug metabolism: an overview.
    Gibson TP
    Am J Kidney Dis; 1986 Jul; 8(1):7-17. PubMed ID: 3524205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of cimetidine on cyclophosphamide metabolism in rabbits.
    Anthony LB; Long QC; Struck RF; Hande KR
    Cancer Chemother Pharmacol; 1990; 27(2):125-30. PubMed ID: 2249327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
    D'Incalci M; Rossi C; Zucchetti M; Urso R; Cavalli F; Mangioni C; Willems Y; Sessa C
    Cancer Res; 1986 May; 46(5):2566-71. PubMed ID: 3697995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.
    Movin-Osswald G; Boelaert J; Hammarlund-Udenaes M; Nilsson LB
    Br J Clin Pharmacol; 1993 Jun; 35(6):615-22. PubMed ID: 8329289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.